Top Markets
#1 NEW X CEO IS BACK NEW X CEO IS BACK +190,916.81%
#2 Beta Finance Beta Finance +8,977.34%
#3 Velas Velas +461.19%
#4 Tribe Tribe +73.83%
#5 Orochi Network Orochi Network +51.29%
#6 Chainbase Chainbase +40.86%
#7 BabyBoomToken BabyBoomToken +34.51%
#8 Freysa AI Freysa AI +33.79%
#9 Block Street Block Street +28.93%
#10 Chrema Coin Chrema Coin +27.48%
Coin of the day
NEW X CEO IS BACK NEW X CEO IS BACK
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Nuformix plc Nuformix plc

Nuformix plc

NFX
Kedudukan dalam Saham #20651
Nuformix plc operates in the field of pharmaceutical development for treating... Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.
Harga Saham
$0.00244926
Modal Pasaran
$51.67K
Perubahan (1 hari)
5.88%
Perubahan (1 tahun)
110.15%
Negara
GB
Perdagangan Nuformix plc (NFX)

Kategori

Healthcare
Nisbah P/E bagi Nuformix plc (NFX)
Nisbah P/E pada March 2026 TTM: -6.38
Menurut laporan kewangan dan harga saham terkini Nuformix plc, nisbah P/E semasa (TTM) ialah -6.38. Pada akhir 2024, syarikat mempunyai nisbah P/E sebanyak -0.13.
Sejarah nisbah P/E bagi Nuformix plc dari 2014 hingga 2026
Nisbah P/E pada akhir setiap tahun
Tahun Nisbah P/E Ubah
2026 (TTM) -6.38 6.76%
2025 -5.98 4,632.12%
2024 -0.13 -96.13%
2023 -3.26 -37.95%
2022 -5.26 -49.52%
2021 -10.42 -58.69%
2020 -25.23 249.86%
2019 -7.21 81.99%
2018 -3.96 -19.00%
2017 -4.89 26.79%
2016 -3.86 0.00%
2014 0.00 0.00%
Nisbah P/E untuk syarikat serupa atau pesaing
Syarikat Nisbah P/E Perbezaan Nisbah P/E Negara
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 10.72 -267.87%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 30.14 -572.17%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 17.03 -366.83%
US
UCB SA UCB SA
UCB SA
UCB.BR
 30.44 -576.78%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
 33.07 -618.05%
AU
Cara membaca nisbah P/E

Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.

Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.

Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.